CIM
EUCRU

Cowen Investment Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Cowen Investment Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100,000
Closed -$1M – 230
2022
Q3 		$1M Hold
100,000
– – 0.22% 120
2022
Q2 		$1M Hold
100,000
– – 0.21% 103
2022
Q1 		$986K Buy
+100,000
New +$992K 0.21% 147

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Cowen Investment Management's EUCRU Position: Q4 2022 in Review

Cowen Investment Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 100,000 shares — an estimated $1M sold.

Cowen Investment Management first reported a position in EUCRU in Q1 2022 and held it in 3 quarters. The position peaked at $1M in Q3 2022. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

  • Cowen Investment Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
  • Cowen Investment Management sold 100,000 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $1M.
  • Cowen Investment Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q1 2022 and held it in 3 quarters.
  • Cowen Investment Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $1M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on Cowen Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.